Use of an antibody to target geldanamycin

Journal of the National Cancer Institute

Volumn 92, Issue 19, 2000, Pages 1549-1551

  Mendelsohn, J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; GELDANAMYCIN; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; COMPLEMENT ACTIVATION; CYTOTOXICITY; DRUG CONJUGATION; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; MEDIATOR; PRIORITY JOURNAL; REVIEW;

EID: 0034605447     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.19.1549     Document Type: Review

References (33)

1. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
2. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breastcancer (MBC)
3. Continuous cultures of fused cells secreting antibody of predefined specificity
4. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell lines
5. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
6. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
7. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
8. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
9. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
10. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
11. A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC)
12. Phase I study of anti-epidermal growth factor receptor (EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)
13. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
14. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
15. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
16. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
17. Regulation of phosphorylation of the C-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells
18. HER-2/neu as a predictive marker of response to breast cancer therapy
19. Therapeutic resistance of erbB-2-overexpressing cancers and strategies to overcome this resistance
20. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines
21. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
22. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
23. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
24. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
25. Addition of Herceptin(TM) (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 +/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial
26. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines
27. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
28. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases
29. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin
30. Inhibition of DNA synthesis in murine tumor cells by geldanamycin, antibiotic of the benzoquinoid ansamycin group
31. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes. Evidence for covalent modification of the p50 subunit
32. Geldanamycin selectively destabilizes and conformationally alters mutated p53
33. Monoclonal antibodies: Basic principles